Sanofi Lawsuit Delays OTC Nasacort Generic Competition
This article was originally published in The Tan Sheet
Executive Summary
Sanofi says with Nasacort Allergy 24HR available at retailers nationwide and online, the firm withdrew its litigation against FDA, which appears to have slowed development of private-label equivalents.
You may also be interested in...
Euro Q1 Consumer Health Earnings Preview: Sanofi, Reckitt, GSK And Bayer
Major Europe-based consumer health players Sanofi, Reckitt, GSK and Bayer feature in this sales and earnings preview, which highlights what to look out for as these four firms report their Q1 2022 results over the coming weeks.
Perrigo Debuts On US National Brand Stage With OTC Switch Approval For Nasonex 24HR Allergy
Nasonex 24HR Allergy also will be first OTC mometasone furoate product available in US. It will compete in OTC intranasal corticosteroids category already led by other brands switched from Rx to nonprescription over past eight years.
Market Exclusivity Decision Pending For Bayer’s First-In-Class OTC Switch Astepro Allergy
Astepro Allergy’s attributes include being the first steroid-free, antihistamine nasal spray for allergies available OTC in the US and the first indicated for indoor and outdoor allergy relief. An attribute yet to be determined will have most influence on revenue boost for Bayer: three-year market exclusivity.